Novatis buy CTIC
By
nndung802000 .
Nov 21, 2012 2:37 PM .
Permalink
Do you think it is possible?
Shares of Cell Therapeutics, Inc. (NASDAQ:CTIC) went straight up on Monday, on word of the licensing terms through which Novartis AG (NYSE:NVS) would be allowed to develop and commercialize Cell’s Pixuvri cancer drug, which was recently okayed by the European Commission. If Novartis elects to exercise its option on Pixuvri, it would owe Cell $7.5 million for a license fee, as much as $104 million in milestone payments, plus ongoing royalties.
Now they just have to pay about 70M. market price of CTIC. A discount price plus 3 other products in phase 3.